Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Leases (2021 - 2025)

Aligos Therapeutics' Current Leases history spans 5 years, with the latest figure at $145000.0 for Q4 2025.

  • For Q4 2025, Current Leases rose 302.78% year-over-year to $145000.0; the TTM value through Dec 2025 reached $145000.0, up 302.78%, while the annual FY2025 figure was $145000.0, 302.78% up from the prior year.
  • Current Leases reached $145000.0 in Q4 2025 per ALGS's latest filing, up from $21000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $3.5 million in Q2 2025 to a low of $4000.0 in Q2 2024.
  • Average Current Leases over 5 years is $1.3 million, with a median of $138000.0 recorded in 2021.
  • Peak YoY movement for Current Leases: tumbled 99.87% in 2024, then surged 87450.0% in 2025.
  • A 5-year view of Current Leases shows it stood at $138000.0 in 2021, then soared by 2099.28% to $3.0 million in 2022, then plummeted by 99.67% to $10000.0 in 2023, then skyrocketed by 260.0% to $36000.0 in 2024, then surged by 302.78% to $145000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Current Leases are $145000.0 (Q4 2025), $21000.0 (Q3 2025), and $3.5 million (Q2 2025).